COVID-19 and Immunodeficiency

Coronaviruses are a type of virus that causes respiratory illnesses such as the common cold and more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) (SARS). The great majority of people with immunodeficiencies and those on immune-suppressing drugs are immunocompromised, putting them at a higher risk of respiratory illnesses. The most common symptomatic primary immunodeficiency in adults is common variable immunodeficiency. Affected patients do not establish an adequate humoral response to community-acquired viral illnesses, and recent findings have found evidence that these patients are more susceptible to severe SARS-CoV-2 infections. The injection of COVID-19 convalescent plasma could be a viable treatment technique in this case.

  • Primary immunodeficiency
  • SARS-CoV-2
  • COVID-19 convalescent plasma
  • Genetic defects

    Related Conference of COVID-19 and Immunodeficiency

    July 11-12, 2022

    International Conference on Vaccine Research

    London, UK
    July 13-14, 2022

    International Conference on Immunology

    London, UK
    August 24-24, 2022

    3rd International Conference on Immunology & Immunotherapies

    Singapore City, Singapore
    August 24-24, 2022

    17th International Conference on Allergy and Clinical Immunology

    Singapore City, Singapore
    September 16-16, 2022

    4th World Conference on Vaccine and Immunology

    Osaka, Japan
    September 16-17, 2022

    International Conference on Immunology Research

    New York, USA
    November 17-18, 2022

    World Congress on Infectious and Contagious Disease

    Berlin, Germany

    COVID-19 and Immunodeficiency Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in